{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:12:51Z","timestamp":1773299571612,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T00:00:00Z","timestamp":1482364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["CVON14-40 DOSIS"],"award-info":[{"award-number":["CVON14-40 DOSIS"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s12471-016-0943-2","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T09:44:15Z","timestamp":1482399855000},"page":"186-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Life-long tailoring of management for patients with hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"25","author":[{"given":"M.","family":"Michels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,22]]},"reference":[{"key":"943_CR1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu199","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, et\u00a0al. 2014 ESC Guidelines on the diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"key":"943_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12471-014-0636-7","volume":"23","author":"EE Wall van der","year":"2015","unstructured":"van der Wall EE. New ESC guidelines on hypertrophic cardiomyopathy: new insights in invasive treatment? Neth Heart J. 2015;23:1\u20133.","journal-title":"Neth Heart J"},{"key":"943_CR3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/cvr\/cvv025","volume":"105","author":"CY Ho","year":"2015","unstructured":"Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY, Pinto Y. Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovasc Res. 2015;105:397\u2013408.","journal-title":"Cardiovasc Res"},{"key":"943_CR4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J\u00a0Am Coll Cardiol. 2015;65:1249\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"943_CR5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026","volume":"5","author":"I Olivotto","year":"2012","unstructured":"Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012;5:535\u201346.","journal-title":"Circ Heart Fail"},{"key":"943_CR6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcmg.2008.08.003","volume":"2","author":"M Michels","year":"2009","unstructured":"Michels M, Soliman OI, Kofflard MJ, et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging. 2009;2:58\u201364.","journal-title":"JACC Cardiovasc Imaging"},{"key":"943_CR7","first-page":"314","volume":"2","author":"CY Ho","year":"2009","unstructured":"Ho CY, Carlsen C, Thune JJ, et\u00a0al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2:314\u201321.","journal-title":"Circ Cardiovasc Genet"},{"key":"943_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1532-429X-12-13","volume":"12","author":"TRI Germans","year":"2010","unstructured":"Germans TRI, G\u00f6tte MJ, Spreeuwenberg MD, et\u00a0al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J\u00a0Cardiovasc Magn Reson. 2010;12:13.","journal-title":"J Cardiovasc Magn Reson"},{"key":"943_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1532-429X-16-28","volume":"16","author":"WP Brouwer","year":"2014","unstructured":"Brouwer WP, Baars EN, Germans T, et al. In-vivo detection of diffuse myocardial fibrosis in hypertrophic cardiomyopathy; a\u00a0CMR study using T1 mapping. J Cardiovasc Magn Reson. 2014;16:28.","journal-title":"J Cardiovasc Magn Reson"},{"key":"943_CR10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"25","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, et\u00a0al. 2011 ACCF\/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: a\u00a0report of the American College of Cardiology foundation\/ American Heart Association Task Force on Practice Guidelines. J\u00a0Am Coll Cardiol. 2011;25:212\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"943_CR11","first-page":"45","volume":"127","author":"MK Jensen","year":"2013","unstructured":"Jensen MK, Havndrup O, Christiaensen M, et\u00a0al. Penetrance of hypertrophic cardiomyopathy in children and adolescents. Circulation. 2013;127:45\u201354.","journal-title":"Circulation"},{"key":"943_CR12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/clc.22293","volume":"37","author":"PA Vriesendorp","year":"2014","unstructured":"Vriesendorp PA, Schinkel AF, de Groot NM, van Domburg RT, Ten Cate FJ, Michels M. Impact of adverse remodeling on sudden cardiac death in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2014;37:493\u20138.","journal-title":"Clin Cardiol"},{"key":"943_CR13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurheartj\/ehr092","volume":"32","author":"I Christiaans","year":"2011","unstructured":"Christiaans I, Birnie E, Bosnel GJ, et\u00a0al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a\u00a0large nationwide cohort of preductively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011;32:1161\u201370.","journal-title":"Eur Heart J"},{"key":"943_CR14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCGENETICS.111.959973","volume":"5","author":"F Pasquale","year":"2012","unstructured":"Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna WJ, Elliott P. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. Circ Cardiovasc Genet. 2012;5:10\u20137.","journal-title":"Circ Cardiovasc Genet"},{"key":"943_CR15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCEP.114.002553","volume":"8","author":"PA Vriesendorp","year":"2015","unstructured":"Vriesendorp PA, Schinkel AF, Liebregts M, et\u00a0al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:829\u201335.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"943_CR16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2015.05.047","volume":"116","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:757\u201364.","journal-title":"Am J Cardiol"},{"key":"943_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccep.2015.03.003","volume":"7","author":"MS Maron","year":"2015","unstructured":"Maron MS. The role of cardiovascular magnetic resonance in sudden death risk stratification in hypertrophic cardiomyopathy. Card Electrophysiol Clin. 2015;7:187\u201393.","journal-title":"Card Electrophysiol Clin"},{"key":"943_CR18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","volume":"100","author":"OP Guttmann","year":"2014","unstructured":"Guttmann OP, Rahman MS, O\u2019Mahony C, Anastakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100:465\u201372.","journal-title":"Heart"},{"key":"943_CR19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","volume":"8","author":"D Pasqualucci","year":"2015","unstructured":"Pasqualucci D, Fornaro A, Castelli G, et\u00a0al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. Circ Heart Fail. 2015;8:1014\u201321.","journal-title":"Circ Heart Fail"},{"key":"943_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","volume":"64","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J\u00a0Am Coll Cardiol. 2014;64:83\u201399.","journal-title":"J Am Coll Cardiol"},{"key":"943_CR21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF03091771","volume":"18","author":"I Christiaans","year":"2010","unstructured":"Christiaans I, Nannenberg EA, Dooijes D, et\u00a0al. Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J. 2010;18:248\u201354.","journal-title":"Neth Heart J"},{"key":"943_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jchf.2013.08.007","volume":"1","author":"T Fujita","year":"2013","unstructured":"Fujita T, Fujino N, Anan R, et\u00a0al. Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy: results from multicenter registration in Japan. JACC Heart Fail. 2013;1:459\u201366.","journal-title":"JACC Heart Fail"},{"key":"943_CR23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/heartjnl-2014-306387","volume":"101","author":"LR Lopes","year":"2015","unstructured":"Lopes LR, Syrris P, Guttmann OP, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294\u2013301.","journal-title":"Heart"},{"key":"943_CR24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCGENETICS.113.000331","volume":"7","author":"Q Li","year":"2014","unstructured":"Li Q, Gruner C, Chan RH, Care M, et al. Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circ Cardiovasc Genet. 2014;7:416\u201322.","journal-title":"Circ Cardiovasc Genet"},{"key":"943_CR25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0025-6196(11)60890-2","volume":"83","author":"I Olivotto","year":"2008","unstructured":"Olivotto I, Girolami F, Ackerman MJ, et\u00a0al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83:630\u20138.","journal-title":"Mayo Clin Proc"},{"key":"943_CR26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.amjcard.2014.05.065","volume":"114","author":"E Biagini","year":"2014","unstructured":"Biagini E, Olivotto I, Iascone M, et al. Significance of carcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol. 2014;114:769\u201376.","journal-title":"Am J Cardiol"},{"key":"943_CR27","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"SD Kristensen","year":"2014","unstructured":"Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC\/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014;35:2383\u2013431.","journal-title":"Eur Heart J"},{"key":"943_CR28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jacc.2011.05.018","volume":"58","author":"I Olivotto","year":"2011","unstructured":"Olivotto I, Girolami F, Sciagra R, et\u00a0al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J\u00a0Am Coll Cardiol. 2011;58:839\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"943_CR29","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","volume":"115","author":"SE Petersen","year":"2007","unstructured":"Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418\u201325.","journal-title":"Circulation"},{"key":"943_CR30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cvr\/cvv024","volume":"105","author":"I Olivotto","year":"2015","unstructured":"Olivotto I, d\u2019Amati G, Basso C, et\u00a0al. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovasc Res. 2015;105:409\u201323.","journal-title":"Cardiovasc Res"},{"key":"943_CR31","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","volume":"41","author":"JG Crilley","year":"2003","unstructured":"Crilley JG, Boehm EA, Blair E, et\u00a0al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J\u00a0Am Coll Cardiol. 2003;41:1776\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"943_CR32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/eurjhf\/hfr135","volume":"13","author":"SA Timmer","year":"2011","unstructured":"Timmer SA, Germans T, Brouwer WP, et\u00a0al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail. 2011;13:1283\u20139.","journal-title":"Eur J Heart Fail"},{"key":"943_CR33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cvr\/cvu127","volume":"103","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends ER, G\u00fc\u00e7l\u00fc A, Germans T, et al. Gene-specific increase in energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res. 2014;103:248\u201357.","journal-title":"Cardiovasc Res"},{"key":"943_CR34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","volume":"363","author":"CY Ho","year":"2010","unstructured":"Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552\u201363.","journal-title":"N Engl J Med"},{"key":"943_CR35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/CIRCRESAHA.112.270041","volume":"111","author":"T Schober","year":"2012","unstructured":"Schober T, Huke S, Venkataraman R, et al. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ Res. 2012;111:170\u20139.","journal-title":"Circ Res"},{"key":"943_CR36","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.111.300436","volume":"112","author":"V Sequeira","year":"2013","unstructured":"Sequeira V, Wijnker PJM, Nijenkamp LLAM, et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res. 2013;112:1491\u2013505.","journal-title":"Circ Res"},{"key":"943_CR37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/cvr\/cvt119","volume":"99","author":"ER Witjas-Paalberends","year":"2013","unstructured":"Witjas-Paalberends ER, Piroddi N, Stam K, et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovas Res. 2013;99:432\u201341.","journal-title":"Cardiovas Res"},{"key":"943_CR38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/cvr\/cvv019","volume":"105","author":"J Velden van der","year":"2015","unstructured":"van der Velden J, Ho CY, Tardiff J, Olivotto I, Knollmann BC, Carrier L. Research priorities in sarcomeric cardiomyopathies. Cardiovasc Res. 2015;105:449\u2013556.","journal-title":"Cardiovasc Res"},{"key":"943_CR39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12471-013-0478-8","volume":"21","author":"A G\u00fc\u00e7l\u00fc","year":"2013","unstructured":"G\u00fc\u00e7l\u00fc A, Germans T, Witjas-Paalberends ER, et al. ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study). Neth Heart J. 2013;21:567\u201371.","journal-title":"Neth Heart J"},{"key":"943_CR40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/cvr\/cvv023","volume":"105","author":"JC Tardiff","year":"2015","unstructured":"Tardiff JC, Carrier L, Bers DM, et\u00a0al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res. 2015;105:457\u201370.","journal-title":"Cardiovasc Res"},{"key":"943_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","volume":"3","author":"CY Ho","year":"2015","unstructured":"Ho CY, Lakdawala NK, Cirino AL, et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a\u00a0pilot randomized trial to modify disease expression. JACC Heart Fail. 2015;3:180\u20138.","journal-title":"JACC Heart Fail"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-016-0943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12471-016-0943-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-016-0943-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T17:12:59Z","timestamp":1568653979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12471-016-0943-2"}},"subtitle":["Awareness and decision-making in changing scenarios"],"short-title":[],"issued":{"date-parts":[[2016,12,22]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1007\/s12471-016-0943-2","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,22]]}}}